NCT00038051View on ClinicalTrials.gov

Evaluation of the Anti-CD-33 Immunotoxin Hum-195/rGel in Patients With Advanced Myeloid Malignancies

PHASE1CompletedINTERVENTIONAL
Enrollment

28

Participants

Timeline

Start Date

May 31, 1999

Primary Completion Date

February 28, 2013

Study Completion Date

February 28, 2013

Conditions
Acute Myeloid LeukemiaChronic Myelomonocytic LeukemiaMyeloproliferative DisordersAnemia, Refractory, With Excess of Blasts
Interventions
DRUG

Hum-195/rGel

Starting Dose = 3 mg/m\^2 twice weekly for 2 weeks.

Trial Locations (1)

77030

UT MD Anderson Cancer Center, Houston

All Listed Sponsors
lead

M.D. Anderson Cancer Center

OTHER